Summit Therapeutics Share Discussion Threads

[kirk 6] 30/9/2019 18:52

Back over 30p now isn't it 1.81 lol

[chrisatrdg] 30/9/2019 18:46

Hi All - Summ is currently 14.38 % up at $1.75 = £0.29p which is the highest rise this year.I also note that we have not had the interim results out yet for the 6 months ended 31st July 2019 which are normally out by now - is there something brewing ?

[kirk 6] 30/9/2019 17:42

1.64 now something might be happening

[kirk 6] 30/9/2019 17:37

Bloody hell 1.61 on Nasdaq what's that equivalent

[kirk 6] 30/9/2019 17:00

More scope for usUp again on the Nasdaq

[waterloo01] 30/9/2019 16:13

See one of the other UK antibiotic plays (Motif) is in it's death throws. They had liver toxicity issues and just ran out of runway to run further trials, which would probably still leave tox issues, so not sure should be any read over to Summit as their demise is mainly the drug, not the broken antibiotic market. IMO

[kirk 6] 28/9/2019 18:49

Good links and very interestingDo you think that is why it closed up over 10% in Nasdaq ?Surely have a good week next week here?

[waterloo01] 28/9/2019 18:35

Well spotted. Direct link below.



Think the Disarm act is slowly heading through Congress as well.

[freedosh] 28/9/2019 18:29

Scroll down to related news and check out. “Use of high risk antibiotics...”;.
Highly relevant to us.

[kirk 6] 28/9/2019 10:37

Great close that's 24.5p equivalent

[chrisatrdg] 27/9/2019 21:27

I note that tonights close on NASDAQ is $1.53 = £0.25p something brewing?

Edit: So far no RNS to say the half year accounts are about to be issued now behind last years dates - is there to be breaking news soon we shall see (hopefully positive news).

[chrisatrdg] 25/9/2019 15:02

RNS Today

Summit Therapeutics to Host R&D Day 7 October 2019

[kirk 6] 24/9/2019 14:23

And there you have it good news again and not only that on the day of the good news people are scrambling to sell at an all time low virtually.

[kirk 6] 24/9/2019 12:48

So much good news after good news after good news yet share price virtually all time lowLet's hope we get some bad news soon

[chrisatrdg] 18/9/2019 10:35

Summit Announces Publication of Editorial in Future Microbiology Advocating for Innovation in Antibiotic Development to Drive Stewardship Focus on Improving Patient Outcomes
Wed, 18th Sep 2019 07:00

Summit Therapeutics plc
(‘Summit’ or the ‘Company’)

Summit Announces Publication of Editorial in Future Microbiology Advocating for Innovation in Antibiotic Development to Drive Stewardship Focus on Improving Patient Outcomes

New Classes of Targeted Antibiotics Support Stewardship and could Combat Resistance
Oxford, UK, and Cambridge, MA, US, 18 September 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announced the publication of a Personal Perspective entitled “Combating Resistance While Maintaining Innovation: The Future of Antimicrobial Stewardship” in the journal Future Microbiology. The paper calls for innovation in the development of antimicrobial products to drive antibiotic stewardship programmes (‘ASPs’) to focus on improving patient outcomes.

“Antimicrobial stewardship calls for the appropriate use of antibiotics to optimise patient outcomes by ensuring the right drug, right dose and duration are administered,” said Professor Cornelius Clancy, Director of the XDR Pathogen Lab at the University of Pittsburgh. “Through our publication, we are advocating for the focus to be on measures directly connected to the patients and on improving their care. I believe evolving the current stewardship programmes will be incentivised by the emergence of innovative antimicrobials designed for specific infectious diseases.”

The concept of antibiotic stewardship arose in the 1970s in response to the emergence of antibiotic resistance. Its purpose was to ensure judicious antibiotic use to optimise clinical outcomes for patients. However, a recent Infectious Disease Society of America (‘IDSA’) survey indicated that 87% of hospital providers in the US considered reducing antibiotic costs a major driver in their ASPs, despite antibiotic cost not being in the definition of antibiotic stewardship. With ASPs to be implemented in all US acute care hospitals by 2020, and numerous stewardship initiatives in Europe, the publication outlines why it is crucial that ASPs are optimised to focus on measures such as resistance, mortality, hospital length of stay and readmission rates. This could encourage use of innovative antibiotics to improve patient outcomes and reduce the total burden of bacterial infections on healthcare systems.

“Our approach to antibiotic drug development aims to end the perception that new antibiotics are ‘break-in-emergency’ treatments. Our lead antibiotic, ridinilazole, is being developing for C. difficile infection, where current treatments fail in about a third of cases. Ridinilazole is a new class antibiotic with a new mechanism of action and our landmark Phase 3 is a superiority clinical trial designed to support the value of its use front-line. Our approach shows how innovation can closely align with good stewardship as we seek to achieve better outcomes for patients,” said Dr David Roblin, President of R&D of Summit.

Targeted spectrum antibiotics have the potential to significantly enhance antibiotic stewardship. With the advances in rapid diagnostics, targeted antibiotics could be developed as front-line treatments for a specific infection, potentially showing clear benefits in patient outcomes over the current standard of care, while allowing use of existing broad-spectrum agents to be reserved. In addition, new classes of antibiotics are likely to circumvent existing resistance mechanisms compared to analogues of current classes where antibiotic resistance already exists.

“Combating Resistance While Maintaining Innovation: The Future of Antimicrobial Stewardship”
=

[kirk 6] 12/9/2019 21:14

Nicely breaking upwards over the pond

[waterloo01] 12/9/2019 11:02

Lack of questions was annoying but the presentation good. Would really like to see the next drug enter via the limited population studies which is so much faster (and cheaper). That might get the motor rolling, along with some funding news/grants.

[chrisatrdg] 12/9/2019 10:37

Hi freedosh - Good to see you posting I hope all is ok.You have been a stalwart on this board & at the AGM's.I for one have had a car crash with this share & expect to have to wait another 2 years.Regards.

[freedosh] 12/9/2019 10:29

Agree Chris. Excellent presentation by Glyn.
I would have been far less polite to the audience at the lack of questions - so it’s good I wasn’t presenting!

[chrisatrdg] 11/9/2019 15:30

I was on holiday yesterday but just listened today to yesterdays presentation per link below - any thoughts from anyone ?



Edit: I thought it was quite punchy but clearly from Glyn's comments on the share price he feels it is I think he said 'pitiful'.In addition it was disappointing that there were no questions.

[gooosed] 11/9/2019 09:25

Thanks waterloo01

Small section on AMR this morning on Sky News - principally about lack of Pharma involvement and recognition of looming global threat . . . nothing SH's were not already aware of but coverage does seem to be increasing.